Linathan

Linagliptin, the active ingredient in Linathan, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycemic control in adults with type 2 diabetes mellitus by enhancing the body’s natural incretin response.

GNH USA supplies Linathan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements.

Linagliptin is used in the management of type 2 diabetes, a chronic metabolic disorder characterized by insulin resistance.

Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels when used with diet and exercise. Adjunct to metformin therapy: provides additional glycemic reduction in patients not achieving targets with metformin alone. Combination therapy: can be co‑administered with other oral antidiabetics to achieve individualized glycemic goals.

Linagliptin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection. - Headache: transient and usually low‑intensity. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: includes nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: such as angioedema or Stevens‑Johnson syndrome. - Hepatic injury: elevated liver enzymes or jaundice.

Before initiating Linathan, clinicians should consider several safety aspects.

Renal impairment: dose adjustment generally not required, but monitor renal function regularly. Hepatic impairment: use with caution; monitor liver enzymes. Cardiovascular disease: evaluate risk‑benefit in patients with heart failure. Elderly patients: monitor for hypoglycemia when combined with insulin or sulfonylureas. Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. Store at ambient temperature: keep in original container, protect from moisture and light.

Linathan can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Rifampin (potent inducer): may reduce linagliptin efficacy. - Combination with insulin or sulfonylureas: increased risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood glucose control. - ACE inhibitors or ARBs: monitor renal function when used together. - Warfarin: monitor INR as glycemic changes can influence anticoagulation.